Talk:Eric Verdin

This article must adhere to the biographies of living persons (BLP) policy, even if it is not a biography, because it contains material about living persons. Contentious material about living persons that is unsourced or poorly sourced must be removed immediately from the article and its talk page, especially if potentially libellous. If such material is repeatedly inserted, or if you have other concerns, please report the issue to this noticeboard.

If you are a subject of this article, or acting on behalf of one, and you need help, please see this help page.

Belgium Low‑importance

	Belgium portal This article is within the scope of WikiProject Belgium, a collaborative effort to improve the coverage of Belgium on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.BelgiumWikipedia:WikiProject BelgiumTemplate:WikiProject BelgiumBelgium-related
Low	This article has been rated as Low-importance on the project's importance scale.

Biography: Science and Academia

	Biography portal This article is within the scope of WikiProject Biography, a collaborative effort to create, develop and organize Wikipedia's articles about people. All interested editors are invited to join the project and contribute to the discussion. For instructions on how to use this banner, please refer to the documentation.BiographyWikipedia:WikiProject BiographyTemplate:WikiProject Biographybiography
	This article is supported by the science and academia work group (assessed as Low-importance).

Medicine Low‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine
Low	This article has been rated as Low-importance on the project's importance scale.

Citing different sources

Latest comment: 7 years ago2 comments2 people in discussion

Part of an edit requested by an editor with a conflict of interest has been implemented. [See below]

Hello, I would like to cite more secondary/tertiary sources for this article.

1. Source for his educational background: https://www.bizjournals.com/sanfrancisco/news/2018/07/05/ceo-eric-verdin-buck-institute-pharma.html
2. Source for his affiliation with UCSF: https://www.northbaybusinessjournal.com/northbay/marincounty/6482105-181/buck-institute-aging-research-biotech-novato
3. Source for HDACs: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3970420/
4. Source for being highly cited: https://scholar.google.com/citations?user=SKFD2LcAAAAJ&hl=en. We will need to actually change the sentence into: "He is a highly cited scientist with h-index of 103 and has been recognized for his research with a Glenn Award for Research in Biological Mechanisms of Aging and a senior scholarship from the Ellison Medical Foundation."
5. Source for the number of patents: https://patents.justia.com/inventor/eric-verdin
6. Source for number of papers: https://scholar.google.com/citations?user=SKFD2LcAAAAJ&hl=en. Can we change the sentence into: "He has published more than 300 scientific papers and currently holds 20 patents."?

Also, I would like to add a sentence about how Dr. Verdin was involved with the launch of a biotechnology company called Napa Therapeutics in August 2018: "Napa Therapeutics, a biotechnology company that focuses on developing drugs against aging-related targets, was built on the NAD metabolism research from Verdin's lab." Here is the source: https://www.biospace.com/article/buck-institute-insilico-med-and-juvenescence-found-napa-therapeutics-to-focus-on-age-related-diseases/.

Thank you! Irenepark89 (talk) 23:38, 14 January 2019 (UTC)Reply

Reply 15-JAN-2019

Below you will see where proposals from your request have been quoted with reviewer decisions and feedback inserted underneath, either accepting, declining or otherwise commenting upon your proposal(s). Please read the enclosed notes within the proposal review section below for information on each request. Spintendo 12:02, 15 January 2019 (UTC)Reply

Proposal review 15-JAN-2019

Source for his educational background: https://www.bizjournals.com/sanfrancisco/news/2018/07/05/ceo-eric-verdin-buck-institute-pharma.html
Unable to implement.^{[note 1]}

Source for his affiliation with UCSF: https://www.northbaybusinessjournal.com/northbay/marincounty/6482105-181/buck-institute-aging-research-biotech-novato
Approved.^{[note 2]}

Source for HDACs: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3970420/
Declined.^{[note 3]}

Source for being highly cited: https://scholar.google.com/citations?user=SKFD2LcAAAAJ&hl=en We will need to actually change the sentence into: "He is a highly cited scientist with h-index of 103 and has been recognized for his research with a Glenn Award for Research in Biological Mechanisms of Aging and a senior scholarship from the Ellison Medical Foundation."
Declined.^{[note 4]}

Source for the number of patents: https://patents.justia.com/inventor/eric-verdin
Approved.^{[note 5]}

Source for number of papers: https://scholar.google.com/citations?user=SKFD2LcAAAAJ&hl=en Can we change the sentence into: "He has published more than 300 scientific papers and currently holds 20 patents."?
Declined.^{[note 6]}

Napa Therapeutics, a biotechnology company that focuses on developing drugs against aging-related targets, was built on the NAD metabolism research from Verdin's lab.
Declined.^{[note 7]}

___________

↑ This reference could not be added because the source is behind a paywall. Please provide a quote of the content by placing the information under the |quote= parameter of the reference template.

↑ The source for this claim ideally would have come from UCSF, as they are the final source on whether the subject has an association with their institution. Nevertheless, the reference was added.

↑ This part of the edit request proposal was declined because the provided source does not state which lab it was who first cloned this family of enzymes. The source provided by the proposed source states that the first histone deacetylase, HDAC1, was isolated and cloned in 1996.^[1] The subject's name is not part of the authors listed in that source.

↑ ~~This part of the edit request proposal was declined because it uses the subjective word highly. The use of that word in the article has been omitted.~~ This word in relation to being cited is acceptable.

↑ According to the provided source, the subject has filed for patents to protect twenty (20) inventions. Of those 20, five (5) have been granted by the United States Patent and Trademark Office (USPTO) while fifteen (15) applications are still pending. The article has been updated to reflect this count with qualifications as provided by the source.

↑ This part of the edit request proposal was declined because the number of patents granted is not verified by the provided source.

↑ This part of the edit request proposal was declined because it is unclear what is meant by the words "was built on."

References

↑ Schreiber, Stuart L.; Hassig, Christian A.; Taunton, Jack (19 April 1996). "A Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p". Science. 272 (5260): 3. doi:10.1126/science.272.5260.408. ISSN 0036-8075.

Request edit

Latest comment: 7 years ago2 comments2 people in discussion

The following Wikipedia contributor may be personally or professionally connected to the subject of this article. Relevant policies and guidelines may include conflict of interest, autobiography, and neutral point of view.

[[User:{{{1}}}|{{{1}}}]] ([[User talk:{{{1}}}|talk]] · [[Special:Contribs/{{{1}}}|contribs]])

Part of an edit requested by an editor with a conflict of interest has been implemented. [See below]

Thank you! I would like to propose the following references and/or addition of new sentences to address the concerns.

1. For "A native of Belgium, Verdin received his Doctorate of Medicine (MD) from the University of Liege and additional clinical and research training at Harvard Medical School. He has held faculty positions at the University of Brussels, the National Institutes of Health (NIH), and the Picower Institute for Medical Research." https://www.northbaybusinessjournal.com/northbay/marincounty/6354003-181/buck-institute-hires-new-ceo

2. "He has an h-index of 103 and has been recognized for his research with a Glenn Award for Research in Biological Mechanisms of Aging in 2010 and a senior scholarship from the Ellison Medical Foundation in 2003." https://scholar.google.com/citations?user=SKFD2LcAAAAJ&hl=en&oi=ao, https://www.ellisonfoundation.org/content/role-sirt3-sir2-related-mitochondrial-protein-deacetylase-aging, and https://glennfoundation.org/awards-programs/glenn-awards/

3. "Napa Therapeutics, a biotechnology company that focuses on developing drugs against aging-related targets, is based on the NAD metabolism research from Verdin's lab." https://www.biospace.com/article/buck-institute-insilico-med-and-juvenescence-found-napa-therapeutics-to-focus-on-age-related-diseases/

Irenepark89 (talk) 21:51, 30 January 2019 (UTC)Reply

Reply 30-JAN-2019

Below you will see where proposals from your request have been quoted with reviewer decisions and feedback inserted underneath, either accepting, declining or otherwise commenting upon your proposal(s). Please read the enclosed notes within the proposal review section below for information on each request. Please note that the COI editor's use of the {{connected contributor}} template is incomplete, as the template has not been filled out. Spintendo 22:44, 30 January 2019 (UTC)Reply

Proposal review 30-JAN-2019

A native of Belgium, Verdin received his Doctorate of Medicine (MD) from the University of Liege and additional clinical and research training at Harvard Medical School. He has held faculty positions at the University of Brussels, the National Institutes of Health (NIH), and the Picower Institute for Medical Research.
Clarification needed.^{[note 1]}

He has an h-index of 103
Approved.^{[note 2]}

and has been recognized for his research with a Glenn Award for Research in Biological Mechanisms of Aging in 2010
Declined.^{[note 3]}

and a senior scholarship from the Ellison Medical Foundation in 2003.
Declined.^{[note 4]}

Napa Therapeutics, a biotechnology company that focuses on developing drugs against aging-related targets, is based on the NAD metabolism research from Verdin's lab.
Clarification needed.^{[note 5]}

___________

↑ Please provide sourcing from the University of Liege. Regarding the "additional clinical research training" at Harvard please specify what this included, and provide sourcing from Harvard. Please provide references from NIH and the PIMR for those claims.

↑ Cite error: There are <ref> tags on this page without content in them (see the help page).

↑ This part of the edit request proposal was declined because the award is not notable in Wikipedia. A subject is considered notable if it has its own Wikipedia page.

↑ This part of the edit request proposal was declined because the subject's financial sources are not notable.

↑ This part of the edit request proposal requires clarification because it is not known what is meant by the phrase "a company....is based on the NAD metabolism research from Verdin's lab". Please delineate how and in what way a company and its day to day operations would be based on clinical lab research.

removing a warning box at the top of the page

Latest comment: 7 years ago5 comments3 people in discussion

Hello, I am the Communications Manager at the Buck Institute for Research on Aging and would like to have the warning removed from the top of our CEO's page. It says: "This article may have been created or edited for undisclosed payments..." I have posted a disclosure statement that i work for the organization for which i am trying to edit the page and the CEO's page. How can i have that warning box removed? There are edits the CEO would like to his page - updates to his bio.

Thank you! Chloe — Preceding unsigned comment added by Chloecaviness (talk • contribs) 18:06, 17 May 2019 (UTC)Reply

Hi, I'll invite Doc James to this discussion; he made the edit at Special:Diff/866651414 and will likely be able to help here.

~ ToBeFree (talk) 18:15, 17 May 2019 (UTC)Reply

You were not the paid editor that edited this page undisclosed though. Additionally you should only post suggestions here and not edit the article directly. Doc James (talk · contribs · email) 10:05, 19 May 2019 (UTC)Reply

@Doc James: - how can i rectify this situation and get that warning box removed? What content do you find questionable and can i do anything to ease your concerns? Chloecaviness (talk) 18:30, 20 May 2019 (UTC)Reply

@Doc James: Hi Doc James, Can you please let me know how i can rectify this issue so you feel comfortable removing that warning box? What content do you find questionable? Chloecaviness 18:05, 22 July 2019 (UTC)Reply

[1] This reference could not be added because the source is behind a paywall. Please provide a quote of the content by placing the information under the |quote= parameter of the reference template.

[2] The source for this claim ideally would have come from UCSF, as they are the final source on whether the subject has an association with their institution. Nevertheless, the reference was added.

[4] This part of the edit request proposal was declined because the provided source does not state which lab it was who first cloned this family of enzymes. The source provided by the proposed source states that the first histone deacetylase, HDAC1, was isolated and cloned in 1996.^[1] The subject's name is not part of the authors listed in that source.

[5] ~~This part of the edit request proposal was declined because it uses the subjective word highly. The use of that word in the article has been omitted.~~ This word in relation to being cited is acceptable.

[6] According to the provided source, the subject has filed for patents to protect twenty (20) inventions. Of those 20, five (5) have been granted by the United States Patent and Trademark Office (USPTO) while fifteen (15) applications are still pending. The article has been updated to reflect this count with qualifications as provided by the source.

[7] This part of the edit request proposal was declined because the number of patents granted is not verified by the provided source.

[8] This part of the edit request proposal was declined because it is unclear what is meant by the words "was built on."

[3] Schreiber, Stuart L.; Hassig, Christian A.; Taunton, Jack (19 April 1996). "A Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p". Science. 272 (5260): 3. doi:10.1126/science.272.5260.408. ISSN 0036-8075.

[9] Please provide sourcing from the University of Liege. Regarding the "additional clinical research training" at Harvard please specify what this included, and provide sourcing from Harvard. Please provide references from NIH and the PIMR for those claims.

[10] Cite error: There are <ref> tags on this page without content in them (see the help page).

[11] This part of the edit request proposal was declined because the award is not notable in Wikipedia. A subject is considered notable if it has its own Wikipedia page.

[12] This part of the edit request proposal was declined because the subject's financial sources are not notable.

[13] This part of the edit request proposal requires clarification because it is not known what is meant by the phrase "a company....is based on the NAD metabolism research from Verdin's lab". Please delineate how and in what way a company and its day to day operations would be based on clinical lab research.

[note 1]

[note 2]

[note 3]

[note 4]

[note 5]

[note 6]

[note 7]

[1]

[note 1]

[note 2]

[note 3]

[note 4]

[note 5]

This page was redesigned at the edge.

A page that knows where it met you.